STOCK TITAN

Medicus Pharma Ltd. (MDCX) DEF 14A Filings

MDCX NASDAQ

Here are the DEF 14A proxy statements from Medicus Pharma Ltd. (MDCX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.

Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) is asking shareholders to authorize unlimited Class A preferred shares and a discretionary Common Share split of up to one pre-split share for every 50 post-split shares at its special meeting scheduled for December 2, 2026.

If approved, the board could set the terms of each preferred-share series without another shareholder vote; it says it has no present intent to issue these shares. At the maximum split ratio, the proposal would substantially reverse the 50-to-one consolidation effected October 12, 2026. The board says it does not intend to choose a ratio it expects would push the bid price below the $1.00 minimum for continued listing on The Nasdaq Capital Market.

The preferred-share and split proposals each require at least two thirds of votes cast; the adjournment proposal requires a majority. Medicus reported 1,899,338 Common Shares outstanding as of October 28, 2026.

Rhea-AI Summary

Medicus Pharma Ltd. is asking shareholders to approve several items at its June 3, 2026 annual and special meeting, including reappointing KPMG LLP as auditor, electing nine directors, and authorizing a share consolidation of up to 50 old common shares for one new share.

The company has 55,164,465 common shares outstanding as of the April 30, 2026 record date and recently received a Nasdaq notice because its share price closed at $0.28, below the $1.00 minimum bid requirement. The board views a potential share consolidation as a tool to help regain compliance and broaden investor appeal, while noting risks that higher prices or continued listing are not assured.